Penserra Capital Management LLC Avadel Pharmaceuticals PLC Transaction History

Penserra Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$7.34 - $11.18 $9,798 - $14,925	-1,335 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.49 - $9.91 $32 - $49	5 Added 0.38%	1,335 $13,000
Q2 2021 Aug 12, 2021	BUY	$6.73 - $9.05 $33 - $45	5 Added 0.38%	1,330 $8,000
Q1 2021 May 13, 2021	SELL	$6.61 - $10.07 $892 - $1,359	-135 Reduced 9.25%	1,325 $11,000
Q4 2020 Feb 12, 2021	BUY	$5.03 - $7.95 $7,343 - $11,607	1,460 New	1,460 $9,000

738K

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $509M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.